Ben R Taylor sold $41k of RXRX
Chief Financial Officer at RECURSION PHARMACEUTICALS, INC.. 13,426 shares at an average of $3.08, traded Feb 18, 2026, filed Feb 19, 2026.
Score components
- +22RoleCFO
- +6Trade size$41k at market
- 0Share of holdings soldSold 1.1% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001601830-26-000020, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | FTax withholding Class A Common Stock10b5-1 | -11,908 | $3.49 | $42k | 1,208,775 | Feb 19, 2026 |
| Feb 18, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -13,426 | $3.08 | $41k | 1,195,349 | Feb 19, 2026 |
Related signals
Other insiders at RECURSION PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 16Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $242k 50,000 shares | -1% | |
| 3Weak | RECURSION PHARMACEUTICALS, INC. | Robert Hershberg director | $125k 25,000 shares | -13% | |
| 22Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan CEO and President | $79k 22,408 shares | -1% | |
| 13Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $100k 30,000 shares | -0% | |
| 21Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $130k 40,000 shares | -4% | |
| 22Weak | RECURSION PHARMACEUTICALS, INC. | Ben R Taylor Chief Financial Officer | $27k 7,956 shares | -1% | |
| 30Weak | RECURSION PHARMACEUTICALS, INC. | Najat Khan CEO and President | $95k 28,298 shares | -1% | |
| 29Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $588k 170,000 shares | -3% | |
| 21Weak | RECURSION PHARMACEUTICALS, INC. | Christopher Gibson Chief Executive Officer | $138k 40,000 shares | -4% | |
| 27Weak | RECURSION PHARMACEUTICALS, INC. | Blake Borgeson director | $924k 220,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.